Polycystic Ovary Syndrome: Diagnosis and Management in 2026

Clinical Practice Update — Diagnostic Criteria, Lifestyle Interventions, Pharmacological Treatment, Fertility Management, and Metabolic Screening

This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.

MDA-PCOS-2026·15 min read

Clinical Focus

Diagnostic criteria (including AMH as alternative to ultrasound), lifestyle management, COCP and metformin therapy, hirsutism treatment, ovulation induction with letrozole, and cardiometabolic screening

Target Audience

Obstetrician-gynaecologists, endocrinologists, family physicians, reproductive endocrinologists, residents, nurse practitioners

Setting

Outpatient gynaecology, endocrinology, primary care, fertility clinics

Source Evidence

•2023 International Evidence-Based Guideline for the Assessment and Management of PCOS (Teede et al.)
•Endorsed by the Endocrine Society, ASRM, ESE, and ESHRE
•ACOG Practice Bulletin No. 194 — Polycystic Ovary Syndrome (2018)
•Legro et al. — Letrozole vs Clomiphene for PCOS Infertility (NEJM, 2014)

Key Clinical Takeaways

PCOS management diagnostic algorithm showing Rotterdam criteria AMH alternative lifestyle COCP metformin and letrozole fertility pathway — Evidence-based approach to PCOS diagnosis and management per the 2023 International Guideline.

1Diagnose PCOS using evidence-based Rotterdam criteria: 2 of 3 features (hyperandrogenism, ovulatory dysfunction, polycystic ovaries) after excluding other causes → Diagnosis
2New in 2023: AMH can now replace ultrasound for the third diagnostic criterion in adults (but NOT in adolescents) → Diagnosis
3When both hyperandrogenism and ovulatory dysfunction are present, ultrasound and AMH are NOT required — diagnosis is simplified → Diagnosis
4Lifestyle intervention is first-line for all patients — no single diet or exercise regimen is superior to another → Lifestyle
5COCPs are first-line pharmacological therapy for menstrual irregularity and hyperandrogenism; prefer lower ethinyl oestradiol doses and preparations with fewer side effects → Pharmacological Therapy
6Metformin is recommended primarily for metabolic features (insulin resistance, glucose, lipids) and has greater efficacy than inositol → Pharmacological Therapy
7Letrozole is the first-line pharmacological treatment for ovulation induction — it has higher live birth rates and lower multiple pregnancy risk than clomiphene → Fertility Management
8Screen all PCOS patients for cardiovascular risk factors, anxiety, depression, and disordered eating → Screening
9Minimise weight bias and stigma — seek permission before weighing and explain weight-related risks → Lifestyle
10PCOS should be considered an enduring, lifelong condition requiring long-term follow-up across the lifespan → Long-Term Care

How Should You Diagnose PCOS?

PCOS is the most common endocrine disorder in reproductive-aged women, affecting 10–13% of this population. Despite this prevalence, diagnosis is frequently delayed and women report dissatisfaction with the diagnostic process. The 2023 International Guideline simplified and strengthened the diagnostic algorithm, building on the evidence-based 2018 criteria which refined the original 2003 Rotterdam consensus.

Diagnose PCOS in adults when at least 2 of the following 3 criteria are present, after excluding other causes: (i) clinical and/or biochemical hyperandrogenism, (ii) ovulatory dysfunction or irregular cycles, (iii) polycystic ovarian morphology on ultrasound or elevated serum anti-Müllerian hormone (AMH). When both hyperandrogenism and ovulatory dysfunction are present, ultrasound and AMH are not required.

Strong Rec High Evidence 2023 Int’l Guideline

In adolescents (defined as ages 10–19 per WHO), require both hyperandrogenism and ovulatory dysfunction for diagnosis. Do not use pelvic ultrasound for PCOS diagnosis until 8 years post-menarche, and do not use AMH in adolescents, due to poor specificity in this age group.

Strong Rec Moderate Evidence 2023 Int’l Guideline

Exclude other aetiologies at all stages of diagnosis using: TSH (thyroid disease), prolactin (hyperprolactinaemia), 17-hydroxyprogesterone (non-classic congenital adrenal hyperplasia), and FSH/LH (if indicated to exclude premature ovarian insufficiency or hypothalamic amenorrhoea). Consider Cushing syndrome and androgen-secreting tumours when clinically appropriate.

Strong Rec High Evidence 2023 Int’l Guideline

Clinical Pearl: Approximately 70% of PCOS patients have both irregular cycles and hyperandrogenism. For these patients, diagnosis is straightforward and does not require ultrasound or AMH testing. The 2023 guideline also recognises hirsutism alone as predictive of biochemical hyperandrogenism in adults, further simplifying the diagnostic process.

Which Pharmacological Therapy Should You Prescribe?

Treatment choice depends on the patient’s primary concern: menstrual regulation, hyperandrogenism, metabolic features, or fertility. Lifestyle intervention should accompany all pharmacological approaches.

PCOS Pharmacological Therapy by Patient Goal

Patient Goal	First-Line	Second-Line	Practical Tip
Menstrual regulation	COCP (prefer EE ≤30 mcg)	Cyclical progestin; metformin	No specific COCP preparation is recommended; balance efficacy, metabolic risk, side effects, cost
Hirsutism / acne	COCP + mechanical laser/light therapy	Anti-androgens (spironolactone, cyproterone) if suboptimal after 6+ months; must use with contraception	Anti-androgens are teratogenic; ensure reliable contraception. Laser ineffective for blond/grey/white hair.
Metabolic features (insulin resistance, glucose, lipids)	Lifestyle + metformin (especially if BMI ≥25)	Anti-obesity agents or bariatric surgery per general population guidelines	Metformin has greater efficacy than inositol for metabolic outcomes. Inositol offers limited clinical benefits.
Fertility (ovulation induction)	Letrozole 2.5–7.5 mg daily ×5 days, starting cycle day 3–5	Clomiphene +/- metformin; gonadotrophins (low-dose) or laparoscopic ovarian surgery; IVF +/- IVM (third-line)	Letrozole: higher live birth rate, lower multiple pregnancy risk vs clomiphene. Contraindicated in pregnancy — confirm negative test first.

Metformin is not routinely recommended in pregnant women with PCOS per the 2023 guideline.
IVF should be offered as third-line therapy when first- and second-line ovulation induction has failed and there is no other absolute indication for IVF.

Note

Letrozole is used off-label for ovulation induction in many countries. Despite its off-label status, it is now recommended as first-line by the 2023 International Guideline based on RCT evidence showing higher live birth rates (27.5%) compared with clomiphene (19.1%) with a lower risk of multiple pregnancies.

Clinical Decision Pathway

Managing PCOS: 5 Steps

Step 1: Diagnose using the simplified algorithm

Irregular cycles + hyperandrogenism → PCOS confirmed (no ultrasound/AMH needed). Otherwise, check for PCOM on ultrasound or elevated AMH to fulfil 2 of 3 criteria. Exclude thyroid disease, hyperprolactinaemia, NCAH.

Step 2: Assess the full burden of disease

Screen for: CVD risk factors (lipids, glucose/OGTT, blood pressure, waist circumference), anxiety and depression, disordered eating, sleep apnoea (especially if BMI elevated), and quality of life.

Step 3: Start lifestyle intervention for all

No specific diet or exercise regimen is superior. Focus on prevention of excess weight gain, overall health, and emotional wellbeing. Minimise weight stigma. Seek permission before weighing.

Step 4: Add pharmacological therapy based on goals

Not seeking pregnancy → COCP for menstrual irregularity/hyperandrogenism; metformin for metabolic features.

Seeking pregnancy → Letrozole first-line for ovulation induction; clomiphene +/- metformin second-line.

Step 5: Plan long-term follow-up

PCOS is a lifelong condition. Reassess metabolic risk periodically, screen for mental health at diagnosis and at life transitions (including perinatally), and adjust management across the lifespan including postmenopause.

Evidence in Context

The 2023 Guideline: What Changed From 2018

The most significant change is the inclusion of AMH as an alternative to ultrasound for defining polycystic ovarian morphology in adults. AMH was highlighted as a rapidly evolving area in 2018 but evidence was insufficient. By 2023, data were strong enough for a formal recommendation. Other key changes include: strengthened recognition of the psychological burden (anxiety, depression, eating disorders), emphasis on weight stigma reduction, confirmation of letrozole as first-line fertility treatment, and clarification that metformin is superior to inositol for metabolic outcomes.

Letrozole vs Clomiphene: The Evidence

The landmark Legro et al. trial (NEJM 2014) randomised 750 anovulatory women with PCOS to letrozole or clomiphene for up to 5 cycles. Letrozole produced higher live birth rates (27.5% vs 19.1%) with a comparable rate of congenital abnormalities and lower risk of twin pregnancies. Multiple subsequent studies and meta-analyses have confirmed this advantage, leading to the 2023 guideline’s strong recommendation of letrozole as first-line.

Metformin vs Inositol: What the 2023 Guideline Says

Inositol has gained popularity as a supplement for PCOS, but the 2023 guideline concludes that metformin has greater efficacy than inositol, which offers limited clinical benefits in PCOS for hirsutism, weight, and ovulation. Metformin remains the recommended agent for metabolic features, particularly in women with BMI of 25 or higher. The guideline does not recommend inositol as a replacement for metformin.

What We Still Don’t Know

What are population-specific AMH thresholds? AMH levels vary by assay, age, ethnicity, and BMI. Standardised, population-specific cut-offs for defining PCOM are still being established.

What is the role of GLP-1 receptor agonists in PCOS? Emerging data suggest that GLP-1 RAs (e.g., semaglutide, liraglutide) may improve metabolic and reproductive outcomes in PCOS, but large-scale RCTs specific to PCOS are needed.

Does metformin in pregnancy improve PCOS outcomes? Metformin is not routinely recommended in pregnant women with PCOS. Some data suggest it may reduce preterm delivery and limit excess gestational weight gain, but a secondary analysis raised concerns about higher childhood BMI in metformin-exposed offspring at age 4.

References

1.Teede HJ, Tay CT, Laven JJE, et al.; International PCOS Network. Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463
2.Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767–793. doi:10.1016/j.fertnstert.2023.07.025
3.Legro RS, Brzyski RG, Diamond MP, et al.; NICHD Reproductive Medicine Network. Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2014;371(2):119–129. doi:10.1056/NEJMoa1313517
4.Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome. Hum Reprod. 2004;19(1):41–47. doi:10.1093/humrep/deh098
5.ACOG Practice Bulletin No. 194. Polycystic Ovary Syndrome. Obstet Gynecol. 2018;131(6):e157–e171. doi:10.1097/AOG.0000000000002656

How to Read the Evidence Tags

Every recommendation carries two tags. These are Medaptly’s own simplified interpretations.

Recommendation Strength

Tag	Meaning	In Practice
Strong Rec	Benefits clearly outweigh risks.	Standard practice.
Moderate Rec	Evidence favours benefit; some uncertainty.	Most patients should receive this.
Conditional Rec	Depends on patient context.	Shared decision-making.
Against	Risks outweigh benefits.	Avoid.

Evidence Quality

Tag	Meaning	Confidence
High Evidence	Multiple RCTs or large prospective cohorts.	Very confident.
Moderate Evidence	Single RCT or large observational studies.	Reasonably confident.
Low Evidence	Expert consensus or small studies.	Less certain.

For full classification systems, consult the original documents in References.

Article Information

For Educational Purposes Only. This is original clinical education content informed by current published guidelines and clinical evidence. It does not constitute medical advice, is not endorsed by any guideline body (the International PCOS Network, Endocrine Society, ASRM, ESHRE, ACOG, or any other organisation), and does not replace individualised clinical judgement, institutional protocols, or local guidelines. Drug dosages should always be verified against current prescribing information. Readers are encouraged to consult the original source guidelines listed in the References section for the full evidence review and complete recommendation sets.